<SEC-DOCUMENT>0001161697-18-000383.txt : 20180726
<SEC-HEADER>0001161697-18-000383.hdr.sgml : 20180726
<ACCEPTANCE-DATETIME>20180726170922
ACCESSION NUMBER:		0001161697-18-000383
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180725
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180726
DATE AS OF CHANGE:		20180726

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			REPRO MED SYSTEMS INC
		CENTRAL INDEX KEY:			0000704440
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				133044880
		STATE OF INCORPORATION:			NY
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-12305
		FILM NUMBER:		18972460

	BUSINESS ADDRESS:	
		STREET 1:		24 CARPENTER RD
		CITY:			CHESTER
		STATE:			NY
		ZIP:			10918
		BUSINESS PHONE:		845-469-2042

	MAIL ADDRESS:	
		STREET 1:		24 CARPENTER RD
		CITY:			CHESTER
		STATE:			NY
		ZIP:			10918
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form_8-k.htm
<DESCRIPTION>FORM 8-K CURRENT REPORT FOR 07-25-2018
<TEXT>
<HTML>
<HEAD>
</HEAD>
<TITLE></TITLE>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<DIV style="width:720px">
<BR>
<P style="margin:0" align=center><B>UNITED STATES</B></P>
<P style="margin:0" align=center><B>SECURITIES AND EXCHANGE COMMISSION</B></P>
<P style="margin:0" align=center><B>Washington, DC 20549</B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0; font-size:12pt" align=center><B>FORM 8-K</B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0; font-size:12pt" align=center><B>CURRENT REPORT</B></P>
<P style="margin:0; font-size:12pt" align=center><B>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0" align=center>Date of Report (Date of earliest event reported)&nbsp;&nbsp;&nbsp;<B><U>July 25, 2018</U></B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0; font-size:14pt" align=center><B><U>REPRO MED SYSTEMS, INC.</U></B></P>
<P style="margin:0" align=center>(Exact name of registrant as specified in its charter)</P>
<P style="margin:0" align=center>&nbsp;</P>
<TABLE style="margin-top:0; font-size:10pt" cellpadding=0 cellspacing=0 align=center>
<TR><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center><B><U>New York</U></B></P>
</TD><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center><B><U>0-12305</U></B></P>
</TD><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center><B><U>13-3044880</U></B></P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center>(State or other jurisdiction<BR>
of incorporation)</P>
</TD><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center>(Commission<BR>
File Number)</P>
</TD><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center>(IRS Employer<BR>
Identification No.)</P>
</TD></TR>
</TABLE>
<P style="margin:0" align=center><BR></P>
<TABLE style="margin-top:0; font-size:10pt" cellpadding=0 cellspacing=0 align=center>
<TR><TD style="margin-top:0" valign=top width=288><P style="margin:0" align=center><B><U>24 Carpenter Road, Chester, New York</U></B></P>
</TD><TD style="margin-top:0" valign=top width=96><P style="margin:0" align=center><B><U>10918</U></B></P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top width=288><P style="margin:0" align=center>(Address of principal executive offices)</P>
</TD><TD style="margin-top:0" valign=top width=96><P style="margin:0" align=center>(Zip Code)</P>
</TD></TR>
</TABLE>
<P style="margin:0" align=center><BR></P>
<P style="margin:0" align=center>Registrant&rsquo;s telephone number, including area code&nbsp;&nbsp;&nbsp;<B><U>(845) 469-2042</U></B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0" align=center><U>not applicable</U></P>
<P style="margin:0" align=center>(Former name or former address, if changed since last report)</P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0; text-align: justify">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">[ &nbsp;] &nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">[ &nbsp;] &nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">[ &nbsp;] &nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">[ &nbsp;] &nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">Emerging growth company &nbsp;[_]</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &nbsp;[_]</P>
<P style="margin:0; text-align: justify">&nbsp;</P>


<HR noshade align="center" width="100%" size="2"><p style='page-break-before:always'></p><PAGE><BR>


<P style="margin:0px; text-align: justify"><B>ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION.</B></P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify">On July 26, 2018, Repro Med Systems, Inc. dba RMS Medical Products (&ldquo;RMS&rdquo;) issued a press release that discussed certain financial results for the three-month period ended June 30, 2018.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify">The press release dated July 26, 2018 announcing the events described in this Item 2.02 is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify"><B>ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.</B></P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify"><B>Replacement of President and Chief Executive Officer and Chairman of the Board</B></P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify">On July 25, 2018, the Board of Directors of RMS replaced Andrew I. Sealfon, President, Chief Executive Officer and Chairman of the Board, effective immediately. &nbsp;Consequently, Mr. Sealfon&rsquo;s employment was terminated. &nbsp;Mr. Sealfon remains a director.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify">Also on July 25, 2018, Daniel S. Goldberger was appointed as President and Chief Executive Officer on an interim basis and as Chairman of the Board, and replaced as the Lead Director.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify">Mr. Goldberger, 59, was appointed to the RMS Board of Directors in April 2018. &nbsp;Mr. Goldberger has over 35 years of experience within the biotech, medical technology, and high tech industries. &nbsp;His areas of expertise include mergers and acquisitions, capital formation, intellectual property, product development, supply chain, business analytics, and turnarounds. &nbsp;Since January 2018, Mr. Goldberger has been the Chief Executive Officer of Synergy Disc Replacement Inc., a private company commercializing a proprietary total disc implant for cervical spine therapy. &nbsp;Prior to this, Mr. Goldberger served as Chief Executive Officer of Milestone Medical, Inc. until October 2017. &nbsp;Prior to this he served as the Chief Executive Officer of Xtant Medical Holdings, Inc. from August 2013 to January 2017. He served as the Chief Executive Officer of Sound Surgical Technologies LLC from April 2007 to February 2013. Mr. Goldberger served on the boards of Xtant Medical Holdings, Inc., Sound Surgical, Xcorporeal and Glucon. He currently serves as an advisor to investment funds Meridian Capital and Wellfleet Capital. Mr. Goldberger earned his B.S. in Mechanical Engineering from M.I.T, his M.S. in Mechanical Engineering from Stanford University and attended the Stanford Directors College. </P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify">The press release dated July 26, 2018 announcing the events described in this Item 5.02 is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify"><B>ITEM 8.01 OTHER EVENTS.</B></P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify"><B>Appointment of Lead Director</B></P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify">On July 25, 2018, the Board of Directors of RMS appointed Joseph M. Manko, Jr., a current RMS director, as Lead Director.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0"><B>ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.</B></P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0; text-align: justify">(d) Exhibits.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 720px">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 96"><U>Exhibit No.</U></TD>
    <TD STYLE="width: 624"><U>Description</U></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>99.1</TD>
    <TD><A HREF="ex_99-1.htm">Press release dated July 26, 2018</A></TD></TR>
</TABLE>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0" align=center><B>SIGNATURES</B></P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0; text-indent:48; text-align: justify">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<TABLE style="margin-top:0; font-size:10pt" cellpadding=0 cellspacing=0 width=100%>
<TR><TD style="margin-top:0" valign=top><P style="margin:0">&nbsp;</P>
</TD><TD style="margin-top:0" valign=top width=360 colspan=2><P style="margin:0">REPRO MED SYSTEMS, INC.<BR>
(Registrant)</P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top><P style="margin:0">&nbsp;</P>
</TD><TD style="margin-top:0" valign=top width=24><P style="margin:0">&nbsp;</P>
</TD><TD style="margin-top:0" valign=top width=336><P style="margin:0">&nbsp;</P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top><P style="margin:0">Date: &nbsp;<U>July 26, 2018</U></P>
</TD><TD style="margin-top:0" valign=top width=24><P style="margin:0">By:</P>
</TD><TD style="margin-top:0" valign=top width=336><P style="margin:0"><U>/s/ Daniel S. Goldberger</U></P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top colspan=2><P style="margin:0">&nbsp;</P>
</TD><TD style="margin-top:0" valign=top width=336><P style="margin:0">Daniel S. Goldberger<BR>
President and Chief Executive Officer</P>
</TD></TR>
</TABLE>
<P style="margin:0"><BR></P>
<P style="margin:0" align=center>- 2 -</P>
<HR noshade align="center" width="100%" size="2">
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>ex_99-1.htm
<DESCRIPTION>PRESS RELEASE DATED 07-26-2018
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<DIV style="width:720px">
<BR>
<P style="margin:0px; font-family:Arial" align=center><B>Exhibit 99.1</B></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><img src="rms_logo.jpg"></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-family:Arial; font-size:12pt" align=center><B>RMS Medical Pre-Announces Strong Quarterly Sales Growth and Change in Leadership</B></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<TABLE style="margin-top:0px; font-size:10pt" cellpadding=0 cellspacing=0><TR height=0 style="font-size:1pt"><TD width=24 ></TD><TD width=696 ></TD></TR>
<TR><TD style="margin-top:0px" valign=top width=24><P style="margin:0px; font-family:Arial">&bull;</P>
</TD><TD style="margin-top:0px" valign=top width=696><P style="margin:0px; font-family:Arial">Quarterly Net Sales increased 17.6% over the comparable period.</P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top width=24><P style="margin:0px; padding:0px">&nbsp;</P></TD><TD style="margin-top:0px" valign=top width=696><P style="margin:0px; padding:0px">&nbsp;</P></TD></TR>
<TR><TD style="margin-top:0px" valign=top width=24><P style="margin:0px; font-family:Arial">&bull;</P>
</TD><TD style="margin-top:0px" valign=top width=696><P style="margin:0px; font-family:Arial">Fifth consecutive quarter of Net Sales growth.</P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top width=24><P style="margin:0px; padding:0px">&nbsp;</P></TD><TD style="margin-top:0px" valign=top width=696><P style="margin:0px; padding:0px">&nbsp;</P></TD></TR>
<TR><TD style="margin-top:0px" valign=top width=24><P style="margin:0px; font-family:Arial">&bull;</P>
</TD><TD style="margin-top:0px" valign=top width=696><P style="margin:0px; font-family:Arial">Announced appointment of Dan Goldberger as Chairman and interim Chief Executive Officer, replacing Andrew Sealfon.</P>
</TD></TR>
<TR><TD style="margin-top:0px" valign=top width=24><P style="margin:0px; padding:0px">&nbsp;</P></TD><TD style="margin-top:0px" valign=top width=696><P style="margin:0px; padding:0px">&nbsp;</P></TD></TR>
<TR><TD style="margin-top:0px" valign=top width=24><P style="margin:0px; font-family:Arial">&bull;</P>
</TD><TD style="margin-top:0px" valign=top width=696><P style="margin:0px; font-family:Arial">Company to announce financial results for the quarter ended June 30, 2018 August 6th with accompanying conference call August 7th.</P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-family:Arial,Times New Roman">CHESTER, N.Y., July 26, 2018 /PRNewswire/ -- Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) today announced top line results for the second quarter ended June 30, 2018 and organizational changes.</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-family:Arial,Times New Roman">Net Sales grew for the fifth consecutive quarter to $4.5 million, a 17.6% increase over $3.8 million reported during the second quarter of 2017. The increase in Net Sales was driven primarily by higher sales of needle sets.</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-family:Arial,Times New Roman">In addition, RMS Medical&rsquo;s Board of Directors has elected Daniel Goldberger, Board Member, to the position of Chairman and interim President and Chief Executive Officer.</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-family:Arial,Times New Roman">&ldquo;I look forward to building on the foundation that Andy has laid over thirty years and we appreciate his service,&rdquo; said Dan Goldberger, RMS Medical&rsquo;s interim Chairman, President and Chief Executive Officer. &ldquo;The invention of the Freedom60 has improved the lives of thousands of chronically-ill patients around the globe, and RMS&rsquo; portfolio of products has enormous application potential. Andy&rsquo;s long list of accomplishments has positioned RMS well for strong long-term growth of revenue and shareholder value.&rdquo;</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-family:Arial,Times New Roman">Mr. Goldberger joined the Board of Directors in April 2018 and is a member of the Governance and Nomination committee. He has held senior leadership and Board of Directors positions at high growth public and private medical technology companies including Xtant Medical Holdings, Sound Surgical Technologies LLC, Xcorporeal and Glucon.</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-family:Arial,Times New Roman">&ldquo;The prospects for the company are very bright, and we are excited to engage new leadership to embark on our next phase of significant growth,&rdquo; stated Joseph Manko, member of the Board of Directors.</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-family:Arial,Times New Roman">The company also announced that it will report financial results for the period ended June 30, 2018 after the close of the market on August 6, 2018. An accompanying conference call will be held on Tuesday, August 7, 2018, at 9:00 AM ET. Please refer to the information below for conference call dial-in information and webcast registration:</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-family:Arial,Times New Roman">Conference date: August 7, 2018, 9:00 AM ET</P>
<P style="margin:0px; font-family:Arial,Times New Roman">Conference dial-in: 877-269-7756</P>
<P style="margin:0px; font-family:Arial,Times New Roman">International dial-in: 201-689-7817</P>
<P style="margin:0px; font-family:Arial,Times New Roman">Conference Call Name: RMS Medical Products (OTCQX: REPR) Second Quarter 2018 Results Call</P>
<P style="margin:0px; font-family:Arial,Times New Roman">Webcast Registration: <FONT style="color:#0000FF">Click Here</FONT></P>
<P style="margin:0px"><BR></P>

<HR noshade align="center" width="100%" size="2"><p style='page-break-before:always'></p><PAGE><BR>

<P style="margin:0px; font-family:Arial,Times New Roman">Following the live call, a replay will be available on the Company&rsquo;s website, www.rmsmedicalproducts.com, under &ldquo;Investor Relations.&rdquo;</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-family:Arial,Times New Roman">About RMS Medical Products</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-family:Arial,Times New Roman">The Company develops, manufactures and commercializes medical products used for home infusions and suctioning. The FREEDOM Syringe Infusion System currently includes the FREEDOM60&reg; and FreedomEdge&reg; Syringe Infusion Drivers, RMS Precision Flow Rate Tubing<font style='font-family:Arial Unicode MS,Times New Roman'>&trade;</font> and RMS HIgH-Flo Subcutaneous Safety Needle Sets<font style='font-family:Arial Unicode MS,Times New Roman'>&trade;</font>. These devices are used for infusions administered in professional healthcare settings as well as at home. The Company&rsquo;s RES-Q-VAC&reg; line of medical suctioning products is used by emergency medical service providers in addition to a variety of other healthcare providers. For more information about RMS Medical Products, please visit <FONT style="color:#0000FF">www.rmsmedicalproducts.com</FONT>.</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-family:Arial,Times New Roman">The results of operations for the periods presented herein are not necessarily indicative of the results to be expected in the future.</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-family:Arial,Times New Roman">Contact:</P>
<P style="margin:0px; font-family:Arial,Times New Roman">For investor inquiries:</P>
<P style="margin:0px; font-family:Arial,Times New Roman">CG Capital</P>
<P style="margin:0px; font-family:Arial,Times New Roman">for RMS Medical Products</P>
<P style="margin:0px; font-family:Arial,Times New Roman">877-889-1972</P>
<P style="margin:0px; font-family:Arial,Times New Roman; color:#0000FF">investorrelations@cg.capital</P>
<P style="margin:0px"><BR></P>

<HR noshade align="center" width="100%" size="2">
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>rms_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 rms_logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !P 8\# 2(  A$! Q$!_\0
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MA_7(]F?M/E*,I7XL?\-7_&+_ **/X@_\"%_^(H_X:O\ C%_T4?Q!_P"!"_\
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M/41GO2U^37CO_@H/\6_%=W)_96H6?A2P_P"65MIUO'))M_VY75F_[Y5:X/\
MX:V^,G_11];_ ._D?_Q%?5PX:QLX<TG%??\ Y'']<I'[0;OK2;D]:_%R3]J_
MXQ2??^)'B#_@$D:_^@I4?_#5?QB_Z*1X@_\  A?_ (BM?]5\5_/'\?\ (7UR
M!^U&4HRE?BQ_PU?\8O\ HH_B#_P(7_XBC_AJ_P",7_11_$'_ ($+_P#$4?ZL
M8O\ GC^/^0_KD>S/VGRE&4K\6/\ AJ_XQ?\ 11_$'_@0O_Q%'_#5_P 8O^BC
M^(/_  (7_P"(H_U8Q?\ /'\?\@^N1[,_:?H.E&5 K\?_ (:?MI?%?PIXSTNZ
MO_%FH>(--\^-+K3]1VR1S1,RJR_<W*WS?+M:OT<_:.;QCI?P]UCQ/X2\:/X8
M.@Z9=ZA+:_V9!=K>[(]ZKND^Y]T_=_OUY&-RFK@JL*5:2]_9ZV_*YK"K&<7*
M/0]C QUI20.]?&'C?Q9\7/#'P8\&:M:_$*35/%/C6^TY-/)T>UA^Q^;9RS/#
MMP1)N8)_WQ7"_&[]K_QMK/PG\+^(/ NJR:%<VV@P:QXCF2UBEQ+-<+:I!AD(
M7]XLS?+Z5E2RRK6Y?9233=KZ_P"75Z+S'[6,3]"J<!31Q7*_$3Q[I7PR\%ZQ
MXGUV<P:=ID!GE*\LW957_:9B%'UKRH^])1MJS<ZVBOC3_AZ!\.O^A;\4?^ \
M'_QZC_AZ!\.O^A;\4?\ @/!_\>KUO[)Q_P#SY9S>WI?S'V117QM_P\_^'/\
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M?^']4<.,^!>IC? #X":Q^T/XOO/#^B:A9Z;<6EFU\\U]O:-U5E3^$%OO25]
M?\.N/B!_T-_AS_OW<_X5E_\ !,V[BL_C?K[SW$=NG]@2?ZR15_Y;Q?WJ_38Z
MSIQ_Y?[;_O\ K_C79G.;8S#8V5*E+2RZ&5"A2E#WC\W?^'7/C_\ Z&_PW_WQ
M<_X4?\.N?'__ $-_AO\ [XN?\*_2/^V]._Y_[;_O^O\ C1_;>G?\_P#;?]_U
M_P :\;_6#,?^?GX(U^JTC\W/^'7/C_\ Z&_PW_WQ<_X4?\.N?'__ $-_AO\
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M[J\_RLZ^1*WEQ(IVJNY?NU\>R?ZNO;P6-I8VE[6EM=K[CFG#V7NR/WN\.?\
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M_%4?VYF?_/S\%_D9_5:7],_/?_AUKXM_Z'?0_P#P#G_^*H_X=:^+?^AWT/\
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M ($R_*W]R.OTC^!GPCT_X*?#/2?"=A^\^RQ;KJY_BN;EN99/^^NE?G'^UO\
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MFC2E6Y+]+6^1]?\ V#BOM2BGZ_\  *__  AOQ/\ [FK_ /@P_P#ME,O/A_\
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M_P" ]S_\;K\>/GH^>OLO]5\+_/+\/\CA^N2['[#_ /#<7P._Z*!9?^ ]S_\
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M^3=K_JIN/N[E'S'^]'_MU]+E-6->,\NKOW*FWDSBKQY;58[H_22BOBCX.?\
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M2^)-P-!?S/LMVK0;/X&;[T?^[N;;7O\ \4/&:>#?#$D\3C[=<9AM4_VO[W_
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M^CC6)+P[XY@BL2%WHP;^*O3MM&!2C5J0ES1D[][ZCY8GGGPP^ O@'X-I<?\
K"'^&+/1IYQB6YCW23R>S2.2W_CU>AFE!S16<I2J2YI.[\P^$?1113 __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
